<qa>  To evaluate the feasibility, safety, and tolerability of venetoclax in combination withII. To evaluate the feasibility, safety, and tolerability of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsedrefractory or previously untreated CLL. 